BioSpace News Archive

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, provided an update on clinical trial progress for KVD824 in development for oral prophylactic treatment of hereditary angioedema.

The board of directors of Medtronic plc on Friday, August 20, 2021, approved the fiscal year 2022 second quarter cash dividend of $0.63 per ordinary share, representing a 9 percent increase over the prior year.

Pfizer Inc. and Trillium Therapeutics Inc. announced that the companies have entered into a definitive agreement under which Pfizer will acquire Trillium, a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer.

Pharma Two B Ltd., a privately held company developing innovative therapeutics based on previously approved drugs for Parkinson disease, announced the appointment of Jeffrey Berkowitz as Chairman of its Board of Directors, effective immediately.

RedHill Biopharma Ltd., a specialty biopharmaceutical company, announced that the U.S. Patent and Trademark Office has issued two new patents, one covering opaganib for treating Ebola virus disease, with patent protection until 2035, and the other covering RHB-104 for treating bacterial infections, with protection through 2029.

Genevant Sciences announced that it has entered into a global collaboration and license agreement with Takeda Pharmaceutical Company Limited for the development and commercialization of novel nonviral gene therapies to treat up to two undisclosed rare liver diseases.

Acerus Pharmaceuticals Corporation today announced that it will participate in the H.C. Wainwright 23rd Annual Global Investment Conference to be held September 13-15 in New York.

Cronos Group, Inc. and Ginkgo Bioworks today announced the achievement of the first target productivity milestone in their partnership to produce eight cultured cannabinoids.

Stealth BioTherapeutics Corp today announced that the United States Patent and Trademark Office has issued patents for Stealth’s lead product candidate, elamipretide, in the U.S. covering the treatment of Barth syndrome and Barth syndrome-related cardiomyopathy until February 2034.

Heat Biologics, Inc. announces the addition of Mark Pryor, former US Senator from the State of Arkansas, to the Company’s Biothreat Advisory Board.